Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Frances H PriddyMerck V520-016 Study Group

Abstract

The safety and immunogenicity of the MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine, a replication-incompetent adenovirus type 5-vectored vaccine designed to elicit cell-mediated immunity against conserved human immunodeficiency virus proteins, was assessed in a phase 1 trial. Healthy adults not infected with human immunodeficiency virus were enrolled in a multicenter, dose-escalating, blind, placebo-controlled study to evaluate a 3-dose homologous prime-boost regimen of the trivalent MRK adenovirus type 5 human immunodeficiency virus type 1 vaccine containing from 3 x 10(6) to 1 x 10(11) viral particles per 1-mL dose administered on day 1, during week 4 and during week 26. Adverse events were recorded for 29 days after each intradeltoid injection. The primary immunogenicity end point was the proportion of study participants with a positive unfractionated Gag-, Pol-, or Nef-specific interferon-gamma enzyme-linked immunosorbent spot response measured 4 weeks after administration of the last dose. Of 259 randomized individuals, 257 (99%) received > or = 1 dose of vaccine or placebo and were included in the safety analyses. Enzyme-linked immunosorbent spot results were available for 217 study...Continue Reading

References

Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·B A LarderD J Purifoy
Oct 1, 1996·AIDS·V BlazevicK J Krohn
Jul 29, 2000·The Journal of Infectious Diseases·N Nathanson, B J Mathieson
Apr 11, 2001·The Journal of Infectious Diseases·R B BelsheUNKNOWN National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (H
Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·Z HelG Franchini
Mar 5, 2002·Nature Medicine·Mark B Feinberg, John P Moore
Jul 2, 2002·Science·Gary NabelJose Esparza
Oct 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zdenek HelGenoveffa Franchini
Sep 27, 2003·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Wendy L TrigonaJohn Shiver
Jan 30, 2004·Annual Review of Medicine·John W Shiver, Emilio A Emini
Feb 10, 2004·The Journal of Infectious Diseases·Rohan JohnDavid H Schwartz
Jun 17, 2004·Statistical Methods in Medical Research·Devan V Mehrotra, Joseph F Heyse
Jun 17, 2004·AIDS·Douglas D RichmanSamuel A Bozzette
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Silvija I StapransMark B Feinberg

❮ Previous
Next ❯

Citations

Jul 20, 2010·JAMA : the Journal of the American Medical Association·Cristine J CooperUNKNOWN NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force
Aug 21, 2010·Immunologic Research·Elizabeth B Wilson, David G Brooks
Nov 1, 2011·Immunologic Research·Adam E SnookScott A Waldman
Oct 19, 2013·International Journal of Oral Science·Fariba S Younai
Jun 17, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lauren A HiraoDavid B Weiner
May 19, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund C J Ertl
Oct 4, 2008·Nature·Dan H Barouch
Jun 7, 2008·Nature Medicine·David I WatkinsWayne C Koff
Dec 8, 2009·Nature Reviews. Microbiology·Simon J Draper, Jonathan L Heeney
Nov 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Erin K QuirkMichael N Robertson
Dec 26, 2008·AIDS Research and Human Retroviruses·Clayton D HarroUNKNOWN Merck V520-007/012 Study Teams
Feb 1, 2011·The Journal of Infectious Diseases·Jacques FellayUNKNOWN NIAID HIV Vaccine Trials Network
Oct 28, 2010·Current Opinion in HIV and AIDS·Jerome H KimNelson L Michael
Dec 4, 2008·AIDS·Lawrence CoreyJames G Kublin
Jun 4, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Olusimidele T AkinsikuPaul A Goepfert
Oct 29, 2010·Journal of Virology·A U BarlanC M Wiethoff
Jan 12, 2010·Annual Review of Medicine·Dan H Barouch, Bette Korber
Dec 29, 2011·The Journal of Clinical Investigation·Nicole FrahmM Juliana McElrath
Jul 23, 2013·Retrovirology·Torben SchiffnerLucy Dorrell
Feb 19, 2010·Virology Journal·Marie-Noëlle TakahashiKatherine E Owen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.